---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110852"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:14:05.062588+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sagimet reports Q3 2025 net loss $12.9M; advances denifanstat + resmetirom combo trial

## Summary
- Net loss for Q3 2025 was $12.9M vs $14.6M YoY; nine-month net loss $41.5M vs $29.4M.
- Cash, cash equivalents and marketable securities totaled $125.5M as of Sept 30, 2025.
- Phase 1 PK trial of denifanstat plus resmetirom in MASH cirrhosis underway; data expected 1H 2026.
- Partner Ascletis completed pre-NDA consultation with China NMPA for denifanstat in acne vulgaris; NDA submission planned.
- Marie O'Farrell promoted to CSO and Liz Rozek to Chief Legal & Admin Officer effective Nov 1, 2025.

## SEC filing metadata
- accession: 0001104659-25-110852
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/0001104659-25-110852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110852
- JSON: https://secwatch.observer/filing/0001104659-25-110852.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.